Nothing Special   »   [go: up one dir, main page]

DE60234496D1 - Virusvektor zur gentherapie - Google Patents

Virusvektor zur gentherapie

Info

Publication number
DE60234496D1
DE60234496D1 DE60234496T DE60234496T DE60234496D1 DE 60234496 D1 DE60234496 D1 DE 60234496D1 DE 60234496 T DE60234496 T DE 60234496T DE 60234496 T DE60234496 T DE 60234496T DE 60234496 D1 DE60234496 D1 DE 60234496D1
Authority
DE
Germany
Prior art keywords
gene therapy
virus vector
infectivity
type
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234496T
Other languages
English (en)
Inventor
Goeran Wadell
Ya-Fang Mei
Anna Segerman
Johan Skog
Kristina Lindman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26655363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60234496(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0100035A external-priority patent/SE0100035D0/xx
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60234496D1 publication Critical patent/DE60234496D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60234496T 2001-01-04 2002-01-04 Virusvektor zur gentherapie Expired - Lifetime DE60234496D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100035A SE0100035D0 (sv) 2001-01-04 2001-01-04 Viral vectors for gene therapy
US26035801P 2001-01-08 2001-01-08
PCT/SE2002/000013 WO2002053759A1 (en) 2001-01-04 2002-01-04 Viral vector for gene therapy

Publications (1)

Publication Number Publication Date
DE60234496D1 true DE60234496D1 (de) 2010-01-07

Family

ID=26655363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234496T Expired - Lifetime DE60234496D1 (de) 2001-01-04 2002-01-04 Virusvektor zur gentherapie

Country Status (6)

Country Link
US (1) US7459153B2 (de)
EP (1) EP1348030B1 (de)
AT (1) ATE449859T1 (de)
AU (1) AU2002217721A1 (de)
DE (1) DE60234496D1 (de)
WO (1) WO2002053759A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20050036989A1 (en) * 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
ES2358204T3 (es) 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
US8216819B2 (en) * 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
EP2916874B1 (de) 2012-11-07 2018-08-29 Council of Scientific and Industrial Research Nanokomplex mit kationischen peptiden zur biomolekülabgabe
AU2014338864C1 (en) 2013-10-25 2020-07-16 Akamis Bio Limited Oncolytic adenoviruses armed with heterologous genes
KR20240032177A (ko) 2015-04-30 2024-03-08 싸이오서스 테라퓨틱스 엘티디. B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
AU9692498A (en) * 1997-10-10 1999-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Complex of biotinylated viral vector and ligand for targeted gene delivery
DK1550722T3 (da) * 1999-05-17 2007-10-08 Crucell Holland Bv Rekombinant human adenovirus serotype 35
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy

Also Published As

Publication number Publication date
WO2002053759A1 (en) 2002-07-11
AU2002217721A1 (en) 2002-07-16
US20040136958A1 (en) 2004-07-15
EP1348030B1 (de) 2009-11-25
AU2002217721A8 (en) 2007-12-06
US7459153B2 (en) 2008-12-02
EP1348030A1 (de) 2003-10-01
ATE449859T1 (de) 2009-12-15
WO2002053759A9 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
DE60234496D1 (de) Virusvektor zur gentherapie
WO2000034308A3 (en) Protein transduction system and methods of use thereof
NL1021701A1 (nl) PEM-brandstofcel.
NZ563785A (en) Mutation in OAS1 genes
GB2448281A (en) Cross connect terminal block
ATE373081T1 (de) Zelllinie
WO2007050405A3 (en) The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
EP1450602A4 (de) Identifizierung und charakterisierung von genen
NO20040649L (no) Forbindelsesanordning, brenselcelle og brenselcellestakk.
CA2529001A1 (en) Binding peptides: methods for their generation and use
WO2007053517A3 (en) Enhanced toggle-mram memory device
WO2002050304A3 (en) Oncolytic virus
CA110297S (en) Wick clip
Li The balance between technology and culture in sustainable architecture
ATE382098T1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
WO2003004610A3 (en) Hsst and angiogenesis
Singh Aalochak Ke Mukh Se
TW200628798A (en) Testing probe
Im What Educational Facilities want with the Private Finance Initiative
Hwang et al. Induction of Oxidative Stress and Cell Death in Neuronal SK-N-MC Cells by Stimulation with 2, 2′, 5, 5′-Tetrachlorobiphenyl (PCB 52)
Shupu Developing Chinese Terminology Research—Terminology Courses Should be Offered in Universties of China
ES1046984U (es) Multicuchillo
Hood Jr The Destructive Power of Religion: Violence in Judaism, Christianity, and Islam
Simeonka Stoykova Introduction, functionality and improvement of individual creditworthiness in Central and Eastern Europe: the Bulgarian case
Seo et al. A Research and Design for the Sungpho High School in Ansan

Legal Events

Date Code Title Description
8363 Opposition against the patent